1. Home
  2. CDT vs ATCH Comparison

CDT vs ATCH Comparison

Compare CDT & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • ATCH
  • Stock Information
  • Founded
  • CDT 2019
  • ATCH 2022
  • Country
  • CDT United States
  • ATCH United States
  • Employees
  • CDT N/A
  • ATCH N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • ATCH
  • Sector
  • CDT Health Care
  • ATCH
  • Exchange
  • CDT Nasdaq
  • ATCH Nasdaq
  • Market Cap
  • CDT 5.2M
  • ATCH 4.4M
  • IPO Year
  • CDT N/A
  • ATCH N/A
  • Fundamental
  • Price
  • CDT $0.69
  • ATCH $0.50
  • Analyst Decision
  • CDT
  • ATCH
  • Analyst Count
  • CDT 0
  • ATCH 0
  • Target Price
  • CDT N/A
  • ATCH N/A
  • AVG Volume (30 Days)
  • CDT 1.4M
  • ATCH 2.0M
  • Earning Date
  • CDT 05-13-2025
  • ATCH 05-27-2025
  • Dividend Yield
  • CDT N/A
  • ATCH N/A
  • EPS Growth
  • CDT N/A
  • ATCH N/A
  • EPS
  • CDT N/A
  • ATCH 2.67
  • Revenue
  • CDT N/A
  • ATCH N/A
  • Revenue This Year
  • CDT N/A
  • ATCH N/A
  • Revenue Next Year
  • CDT N/A
  • ATCH N/A
  • P/E Ratio
  • CDT N/A
  • ATCH $0.24
  • Revenue Growth
  • CDT N/A
  • ATCH N/A
  • 52 Week Low
  • CDT $0.65
  • ATCH $0.54
  • 52 Week High
  • CDT $350.00
  • ATCH $99.00
  • Technical
  • Relative Strength Index (RSI)
  • CDT 31.97
  • ATCH 27.93
  • Support Level
  • CDT $0.65
  • ATCH $0.87
  • Resistance Level
  • CDT $1.05
  • ATCH $1.10
  • Average True Range (ATR)
  • CDT 0.14
  • ATCH 0.10
  • MACD
  • CDT 0.07
  • ATCH 0.08
  • Stochastic Oscillator
  • CDT 7.30
  • ATCH 0.91

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: